Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

WuXi Advanced Therapies’ AAV TESSA Technology to be Licensed to Janssen

Banner
Anna Osborne
17 August 2022
SHARE NOW
Cell Therapy
Collaborations, Mergers & Acquisitions
Finance & Investment
Gene Therapy
Viral/Non-Viral Vectors
The Contract Testing, Development and Manufacturing Organization (CTDMO) WuXi Advanced Therapies (WuXi ATU), has announced that it will license its advanced AAV technology, TESSA, and its proprietary clonal suspension HEK293 cell line to Janssen Biotech, of Johnson & Johnson.

TESSA – Tetracycline-Enabled Self-Silencing Adenovirus – technology is a state-of-the-art novel process for GMP standard, scalable, and, transfection-free manufacture of adeno-associated viral (AAV) vectors, developed by WuXi ATU company OXGENE, in the UK.

“We are honored that Janssen selected WuXi ATU’s TESSA™ technology. We remain committed to improving the TESSA™ platform to produce faster and more cost effective AAV products for patients,” commented David Chang, CEO of WuXi Advanced Therapies.

 

WuXi’s TESSA system can successfully be scaled up to 200L, producing 10 times more AAV than traditional methods of AAV manufacturing, as well as resulting in a significantly higher percentage of full AAV capsids. This greatly reduces overall production costs in comparison to standard plasmid-based AAV systems.

How are you enjoying this news article? Let us know your thoughts, here >>

TESSA offers an efficient and cost-effective solution to meet industry demand for large-scale high-quality AAV manufacturing – delivering more accessible life-changing therapeutics to patients as quickly as possible.

Janssen will utilize TESSA’s applications for their own AAV production, and, HEK293 cell line for the research and development of its advanced therapies.

“The TESSA™ system is a game changer for the manufacture of AAV and the advancement of cell and gene therapies to benefit patients. By improving scalability, reducing process complexity and lowering the costs of gene therapy manufacture, TESSA™ will better enable our global partners to develop and deliver life-saving gene therapies faster to more patients in need,” Dr. Ryan Cawood, CSO of WuXi ATU, noted upon TESSA’s launch earlier this year.

Listen to Ryan Cawood explain more about TESSA in this Tech Demo.

Source: WuXi ATU Press Release


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.

More like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023

Discover more like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

Broken String Bioscience Closes $15M Series A Funding Round

FDA Delays the Review of Iovance’s BLA Treatment of Advanced Melanoma

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022